Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

Moore, Kathleen N., O'Malley, David M., Vergote, Ignace · Gynecologic Oncology · 2018